

and National Society of Genetic Counselors (NSGC) recommend genetic counseling and testing (GC/GT) for 100% of EOC patients.

**Methods:** We analyzed data from 557 women who were diagnosed with advanced EOC from 2001–2015 treated at a single-center cancer center. Information on demographics and socioeconomic status (age, race, education, marital status, children, insurance type), tumor characteristics (site of origin, grade, stage, histotype, debulking status, platinum sensitivity), treatment (sex of gynecologic oncologist, type of chemotherapy provider, clinical trial enrollment, number of therapy lines), survival (progression-free and overall), and referral to genetics counseling was abstracted from medical records. We used logistic regression models to estimate age-adjusted odds ratios and 95% confidence intervals for referral to genetics counseling according to each variable. Stepwise logistic regression was used to identify the most important predictors of genetics counseling referral, with  $p < 0.3$  as the model entry criterion and  $p < 0.2$  as the criterion for staying in the model.

**Results:** Overall, 29% of the ovarian cancer patients had been referred for genetic counseling. Higher educational level, female gynecologic oncologist, clinical trial participation, >1 line of therapy and longer survival were associated with greater likelihood of genetics counseling referral in age-adjusted models. Older age, non-serous histotype, suboptimal debulking status, platinum resistance and medical oncologist as chemotherapy provider were associated with lower likelihood of genetic counseling referral. Ten variables were selected as the most important predictors of referral during stepwise regression: younger age, white race, not having private insurance, professional school education, stage IV vs. III cancer, platinum sensitivity, being treated by a female gynecologic oncologist, having chemotherapy provided by a gynecologic oncologist, clinical trial enrollment, and longer overall survival.

**Conclusions:** Only 20–30% of EOC patients are referred to GC/GT on a nationwide level and similar results were found at our institution. Unique predictive factors will contribute to quality improvement and should be validated at a multi-institutional level to ensure the gold standard of care is provided to all EOC patients.

doi:10.1016/j.ygyno.2019.03.191

#### Poster #2

##### Treatment with paclitaxel causes upregulation in resistance protein tubulin beta III in a type 2 human endometrial cancer cell line

A. Palileo, M. Munoz-Sagastibelza, L. Martello-Rooney. *State University of New York Downstate Medical Center, Brooklyn, NY*

**Objectives:** The goal of this study is to test the hypothesis that paclitaxel-encapsulated microparticles (PMPs) are a feasible cytotoxic treatment modality in an in vitro model of a Type 2 uterine carcinoma cell line. Poly(lactic-co-glycolic acid)-based (PLGA) microparticles (MPs) are a promising new tool for delivery of cytotoxic chemotherapies. These MPs have the benefit of eluting drugs over a period of weeks for sustained pharmacokinetic effect, which may have a benefit in treating Type 2 endometrial adenocarcinomas that are associated with chemoresistance. Part of this evaluation included evaluating the cell line for resistance to paclitaxel. Overexpression of tubulin beta 3 (TUBB3) has been linked to paclitaxel resistance in many cancers including uterine carcinomas.

**Methods:** PMPs were prepared using established laboratory procedure to encapsulate 15mM paclitaxel in DMSO using a water/oil/water (W/O/W) method. Blank microparticles (BMPs) were formulated by repeating the process with DMSO only and used as a control. The human endometrial adenocarcinoma type 2 cell line KLE were plated in 6 well plates at a density of  $2 \times 10^5$  cells and treated with

BMPs and varying volumes of the 15mM PMPs (20, 40, and 60  $\mu$ L). Cells were incubated for 6 days then harvested and underwent western blot analysis for cleaved PARP and TUBB3 with GAPDH loading control. Western Blot intensity was compared to controls for significance using t-test.

**Results:** Cells treated with PMPs showed decrease in cell density with morphologic changes consistent with apoptosis. For PMPs, increasing volumes showed an intensifying effect. Western Blot analysis for cleaved PARP, a byproduct of apoptosis, showed significant 9–17-fold increase in cells treated with PMPs compared to the control group. WB analysis also revealed an absence of TUBB3 in the controls. After treatment with PMPs, there was a statistically significant increase in TUBB3 for 40  $\mu$ L ( $p = 0.02$ ) and 60  $\mu$ L ( $p = 0.01$ ). There was an increase in TUBB3 at 20  $\mu$ L of PMPs, but this did not show significance ( $p = 0.09$ )

**Conclusions:** PLGA encapsulated paclitaxel is a feasible method to deliver cytotoxic chemotherapy in an in vitro model, as evidenced by gross morphologic changes and activation of apoptosis. This study also represents the first demonstration biochemically of upregulation of a resistance marker for paclitaxel as a response to treatment in a cell line that is negative for tubulin beta 3 prior to treatment.

doi:10.1016/j.ygyno.2019.03.192

#### Poster #3

##### Does A1c predict surgical complications? A retrospective chart review of patients with Type II Diabetes Mellitus and Endometrial Cancer

A. Straubhar<sup>a</sup>, M. Dodson<sup>b</sup>, K. Szczotka<sup>a</sup>, S. Soisson<sup>c</sup>, P. Soisson<sup>b</sup>. <sup>a</sup>Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT. <sup>b</sup>Division of Gynecologic Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. <sup>c</sup>Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah

**Objectives:** The purpose of this study is to determine if patients diagnosed with Endometrial Cancer (EC) and Type II Diabetes Mellitus (DMII) are at increased risk for postoperative complications when compared to EC patients without DMII, and if preoperative A1c level influences risk.

**Methods:** This retrospective chart review included all women with EC ICD9 codes who underwent surgery and had follow up within 3 months at one of our facilities between Jan 2009– May 2017. Exclusion criteria included use of neoadjuvant therapies, and patients with a diagnosis of prediabetes receiving treatment. We defined DMII via past medical history documentation, an A1c > 6.5% at any time, or a day of surgery fasting blood glucose >126 mg/dL. We extracted A1c levels within 90 days of the surgery date to assess correlation with post-operative outcomes based upon A1C <8.0% and A1C  $\geq$ 8.0%. We used EC patients without DMII as controls. Post-operative complications included readmission, transfusion, urinary tract infection, wound infection, wound dehiscence, wound seroma, wound hematoma, intrabdominal hematoma, facial dehiscence, vaginal cuff dehiscence, vaginal cuff infection, intrabdominal abscess, ileus, fever, VTE, psychosis, pneumonia, recurrence of disease, and mortality. Complications are listed in table 1 and were manually extracted from chart review. Multi variable models were used to compare the groups.

**Results:** We included 400 women with EC: 86% had Type I disease and 85.4% were Stage I. Overall, 44% of cases were laparotomies and 56% were laparoscopic. DMII was diagnosed in 29% (n=114) cases. In patients with DMII, 51% (n=58) of cases were laparoscopic and 49% (n=56) were laparotomies. DMII patients who underwent laparotomies were at significant risk for overall complications (OR 4.97, 95% CI: 1.96–12.64) and infectious/wound complications (OR 5.32, 95% CI: